Company Contents
Quick Facts & Snapshot
Summary
The Biologics Contract Manufacturing market is entering a scale-up phase, driven by complex biologics, biosimilars, and cell and gene therapies. Leading CDMOs are consolidating share through global bioreactor capacity, specialized platforms, and quality track records. Between 2025 and 2032, the market is projected to grow from US$ 21.10 Billion to US$ 43.49 Billion at a 10.90% CAGR.
Source: Secondary Information and ReportMines Research Team - 2026
Ranking Methodology
Rankings of Biologics Contract Manufacturing market companies are derived from a composite scoring framework that integrates quantitative and qualitative indicators. Core metrics include estimated 2025 biologics CDMO revenue, growth versus the 10.90% market CAGR, project win rates in monoclonal antibodies, recombinant proteins, vaccines, and advanced therapies, as well as installed bioreactor capacity across stainless-steel and single-use platforms. We also assess technology differentiation, such as proprietary expression systems, continuous bioprocessing, and high-titer upstream processes, alongside portfolio breadth from development to commercial fill-finish. Geographic service coverage, regulatory inspection track record, and the ability to execute long-term, multi-asset manufacturing and lifecycle management contracts further influence scores. Each company receives normalized sub-scores that are weighted and aggregated to produce the final ranking, ensuring consistency, transparency, and comparability across Biologics Contract Manufacturing market companies of different sizes and regional footprints.
Top 10 Companies in Biologics Contract Manufacturing
Source: Secondary Information and ReportMines Research Team - 2026
Detailed Company Profiles
Samsung Biologics
Samsung Biologics is a scale leader in biologics contract development and manufacturing, offering end-to-end services from cell line development to commercial supply.
Lonza Group
Lonza is a diversified life sciences CDMO with strong positions in biologics, cell and gene therapy, and small molecules across global facilities.
Catalent, Inc.
Catalent provides integrated biologics development, drug substance, fill-finish, and delivery services with a strong position in complex injectable products.
Thermo Fisher Scientific (Patheon)
Thermo Fisher’s Patheon business offers end-to-end biologics and vaccine CDMO services integrated with analytical, logistics, and clinical supply capabilities.
Boehringer Ingelheim BioXcellence
Boehringer Ingelheim BioXcellence is the biologics CDMO arm of Boehringer Ingelheim, focused on large-scale mammalian and microbial manufacturing.
WuXi Biologics
WuXi Biologics is a fast-growing, platform-centric CDMO offering integrated services from discovery to commercial manufacturing with a strong Asia-Pacific presence.
Fujifilm Diosynth Biotechnologies
Fujifilm Diosynth Biotechnologies focuses on complex biologics and vaccines with strong technical capabilities across mammalian and microbial systems.
Samsung Biopis CDMO Division
Samsung Biopis CDMO Division specializes in biosimilar and late-stage biologics manufacturing, leveraging shared infrastructure with Samsung Biologics.
Rentschler Biopharma SE
Rentschler Biopharma is a specialized CDMO focusing on high-complexity and high-value biologics for orphan and rare diseases.
AGC Biologics
AGC Biologics is a multi-modality CDMO offering mammalian, microbial, plasmid DNA, and cell therapy manufacturing for clinical and commercial stages.
SWOT Leaders
Samsung Biologics
SWOT Snapshot
Unmatched global bioreactor capacity, strong regulatory track record, competitive costs, and robust partnerships with top-20 pharma.
High capital expenditure requirements and concentration of major assets within a single metropolitan cluster.
Growing outsourcing of complex biologics, biosimilars, and ADCs from big pharma and specialty biotechs worldwide.
Pricing pressure from Asian peers, technology disruption from continuous bioprocessing, and potential regional regulatory changes.
Lonza Group
SWOT Snapshot
Deep experience across biologics and advanced therapies, strong innovation culture, and premium positioning with large pharma clients.
Complex multi-technology portfolio raises operational complexity and can dilute management focus across segments.
Rising demand for integrated CGT and biologics solutions and long-term strategic manufacturing partnerships.
Intensifying competition from specialized CGT CDMOs and internalization by large pharma customers.
Catalent, Inc.
SWOT Snapshot
Strong fill-finish network, advanced delivery technologies, and integrated biologics plus drug product capabilities.
Previous operational challenges at select sites have impacted perception and require sustained remediation.
Biopharma preference for single-partner solutions from cell line development through commercial drug product.
Increased scrutiny from regulators and clients, alongside capacity investments by rivals and in-house pharma facilities.
Biologics Contract Manufacturing Market Regional Competitive Landscape
North America remains the largest demand center for Biologics Contract Manufacturing market companies, fueled by a dense pipeline of monoclonal antibodies, oncology biologics, and cell and gene therapies. Catalent, Thermo Fisher Scientific (Patheon), and AGC Biologics leverage proximity to big pharma and biotech clusters in Boston, New Jersey, California, and Texas for steady project inflows.
Europe combines innovation with stringent regulation, favoring Biologics Contract Manufacturing market companies that demonstrate quality and compliance depth. Lonza, Boehringer Ingelheim BioXcellence, Fujifilm Diosynth Biotechnologies, and Rentschler Biopharma operate major hubs in Switzerland, Germany, the U.K., and Denmark, supported by strong public funding, biosimilar uptake, and robust intellectual property frameworks.
Asia-Pacific is the fastest-growing regional arena, where Samsung Biologics, WuXi Biologics, and Samsung Biopis CDMO Division aggressively scale capacity and win global mandates. Governments in South Korea, China, and Singapore are prioritizing biologics manufacturing as strategic infrastructure, encouraging partnerships with Western innovators and accelerating local biotech ecosystem development.
In Latin America, biologics CDMO capacity remains relatively limited, but demand for vaccines, insulin, and oncology biologics is rising. Biologics Contract Manufacturing market companies primarily serve the region through exports from North America and Europe, while select players explore local partnerships and technology-transfer agreements with Brazilian and Mexican public sector institutions.
The Middle East and Africa region is still nascent for biologics manufacturing, yet several Gulf countries are investing in localized biopharma capacity and pandemic-preparedness infrastructure. Global Biologics Contract Manufacturing market companies, including Lonza and Thermo Fisher, increasingly evaluate partnership or joint-venture models to serve regional vaccine, monoclonal antibody, and plasma-derived product needs.
Across all regions, regulatory expectations for data integrity, supply resilience, and environmental sustainability are rising. Leading Biologics Contract Manufacturing market companies differentiate through multi-region networks, digitalized operations, energy-efficient facilities, and the ability to balance cost competitiveness with high-quality, inspection-ready processes.
Biologics Contract Manufacturing Market Emerging Challengers & Disruptive Start-Ups
Emerging Challengers & Disruptive Start-Ups
Niche CDMO integrating biologics development, analytics, and early clinical manufacturing with strong expertise in complex, small-batch biologics and tailored project support.
Building cost-efficient, single-use biologics manufacturing parks targeting biosimilar and emerging-market clients through modular facility design and competitive pricing.
Specializes in process development and clinical-scale manufacturing using advanced analytics, high-throughput screening, and intensified bioprocessing approaches for complex biologics.
Offers integrated biologics and vaccine manufacturing with competitive India-based cost structure, targeting emerging markets and value-focused innovators with flexible capacity models.
Provides fully integrated biologics discovery-to-manufacturing services with strong focus on antibody-drug conjugates and complex biologics requiring customized development strategies.
Combines biologics safety testing and niche manufacturing services, offering virus and adventitious agent testing integrated with small-scale GMP production capabilities.
Biologics Contract Manufacturing Market Future Outlook & Key Success Factors (2026-2032)
From 2025 to 2031, cumulative investments in metro expansions and station safety upgrades are projected to surpass significant amounts. The total market will scale from US$ 2.27 Billionin 2025 to US$ 3.38 Billion by 2031, reflecting a 6.90% CAGR. Winning Biologics Contract Manufacturing market companies will share several attributes. First, they will embed native IoT sensors, enabling predictive maintenance contracts that can double recurring revenue within five years. Second, modular design philosophies—interchangeable panels, plug-and-play controllers—will shorten installation windows and appeal to cost-sensitive public operators.
Localization strategies will also define competitive edges. Suppliers that establish regional assembly plants to meet content rules in India, Brazil, or the U.S. are likely to capture bonus points in tenders. Finally, sustainability credentials will move from optional to mandatory. Recyclable composite panels, energy-efficient brushless motors, and life-cycle carbon disclosures will become bid differentiators. In short, the coming decade rewards Biologics Contract Manufacturingmarket companies that marry digital intelligence with manufacturing agility and regulatory foresight.
Frequently Asked Questions
Find answers to common questions about this company report.